A Q&A with Peter Fromen, CEO of biomodal, emphasising the potential applications of their technology, particularly in oncology, liquid biopsy, aging, and neurodegenerative disorders.
Enrichment protocols enable deep interrogation of target areas whilst maintaining cost effectiveness. Two enrichment methods performed with the duet multiomics solution +modC are presented here.
Joint genetic and epigenetic sequencing technology leads to improved genetics compared to existing methylation calling methods
There is more to DNA than the genetic alphabet A, C, G and T. Epigenetics plays a causal role in cell fate, ageing and disease development.
The Aparicio lab at the British Columbia Cancer Research Centre (BCCRC) utilises 5-letter sequencing technology, duet multiomics solution +modC, to investigate ‘epigenetic rewiring’ in breast cancer cells.
Learn how simultaneous measurement of genetics and epigenetics with duet multiomics solution +modC enables the study of allele-specific methylation and how this can be used to understand the impact of epigenetic rejuvenation.
Review performance of duet multiomics solution +modC for the detection of genetic and epigenetic sequence data at base resolution when using formalin damaged DNA. Samples include formalin-compromised DNA standards (fcDNA) as well as DNA extracted from formalin-fixed and paraffin-embedded (FFPE) samples of two colorectal cancer (CRC) patients.
Learn how duet multiomics solution +modC is transforming research efforts in early cancer detection, risk stratification, and disease monitoring by using liquid biopsy for profiling of cfDNA. This poster illustrates how capturing complete genetic and epigenetic information in one workflow, from a single low-volume DNA sample is more powerful for early disease detection than either alone.
biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single low volume sample. The duet multiomics solution is the world’s first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a single sample, with […]
It all started with an epigenetic discovery Since Cambridge Epigenetix began in 2012, we’ve been innovating in the field of DNA sequencing and epigenetics. Back then, when Shankar Balasubramanian and Bobby Yerramilli‑Rao founded the company, the world was just starting to understand what epigenetic modifications meant to health and disease. We’d developed ways to measure […]